Key clinical point:
Major finding: Factors significantly associated with no systemic treatment included older age (adjusted odds ratio, 1.07 per year), African American descent (aOR, 1.26), and dual Medicare-Medicaid enrollment (aOR, 1.21).
Study details: A retrospective cohort analysis including data on 3,814 patients with active multiple myeloma in the Surveillance, Epidemiology, and End Results–Medicare database from 2007 to 2011.
Disclosures: The research was supported by the National Cancer Institute. The investigators reported having no financial disclosures.
Source: Fakhri B et al. Clin Lymphoma Myeloma Leuk. Mar 2018;18(3):219-24.
Fakhri B et al. Clin Lymphoma Myeloma Leuk. Mar 2018;18(3):219-24.
This Week's Must Reads
Observational study shows hydroxyurea well tolerated in sickle cell disease, Dauvergne B et al. FSCDR 2018, presentation JSCDH-D-18-00052
CAVEAT shows venetoclax plus chemo appropriate for older, fit AML patients , Wei AH et al. EHA Congress, Abstract S1564.
Large cohort study demonstrates DOAC safety vs. warfarin , Vinogradova Y et al. BMJ 2018;362:k2505.
Patients who develop AML may have detectable mutations years earlier, Desai P et al. Nat Med. 2018;24:1015-23.
Oral administration of arsenic + ATRA effective for APML, Zhu HH et al. Lancet Oncol. 2018;19:871-9.
Must Reads in Multiple Myeloma
Lenalidomide-refractory MM responds to triple therapy, Chari A et al. J Clin Oncol 36, 2018 (suppl, abstr 8002).
Added pomalidomide reduced risk of progression, death in myeloma, Richardson PG et al. ASCO 2018, Abstract 8001.
Ruxolitinib add-on boosted myeloma response, Berenson JR, et al. J Clin Oncol 36, 2018, suppl. (ASCO 2018, annual meeting of the American Society of Clinical Oncology); abstr 8005.
Refractory myeloma may respond to ruxolitinib add-on, Berenson JR, et al. J Clin Oncol 36, 2018 (suppl; abstr 8005).
Add-on ibrutinib boosted response in relapsed multiple myeloma, Chari A et al. Leuk Lymphoma. 2018 Apr 4. doi: 10.1080/10428194.2018.1443337.